Personalized healthcare: How to improve outcomes by increasing benefit and decreasing risk through the use of biomarkers

Biomarkers in Medicine

Volumn 3, Issue 6, 2009, Pages 701-709

  Vargas, Gabriel A ^a  

^a Clinical Research and Exploratory Development   (Switzerland)

Author keywords

Alzheimer's disease; Benefit; Biomarker; Herceptin ; HIV; Maraviroc; Personalized healthcare; Personalized medicine; Risk

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; CETUXIMAB; ENFUVIRTIDE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; K RAS PROTEIN; MARAVIROC; PANITUMUMAB; TRASTUZUMAB;

ALZHEIMER DISEASE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; GENETIC RISK; GENETIC VARIABILITY; HEALTH CARE MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NEUTROPENIA; ONCOLOGY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION;

EID: 75149149583     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.74     Document Type: Review

References (50)

1. Lesko LJ: Personalized medicine: elusive dream or imminent reality? Clin. Pharmacol. Ther. 81(6), 807-816 (2007).
2. Woodcock J: The prospects for 'personalized medicine' in drug development and drug therapy. Clin. Pharmacol. Ther. 81(2), 164-169 (2007).
3. Kohane IS: The twin questions of personalized medicine: who are you and whom do you most resemble? Genome Med. 1(1), 4 (2009).
4. Cohen SN, Chang AC, Boyer HW et al.: Construction of biologically functional bacterial plasmids in vitro. Proc. Natl Acad. Sci. USA 70(11) (1973).
5. Waterston RH, Lander ES, Sulston JE: On the sequencing of the human genome. Proc. Natl Acad. Sci. USA 99, 3712-3716 (2002).
6. Venter D: A part of the human genome sequence. Science 299, 1183-1184 (2003).
7. Molnár Z: Timeline: Thomas Willis (1621-1675), the founder of clinical neuroscience. Nat. Rev. Neurosci. 5, 329-335 (2004).
8. Sindrup SH, Brøsen K: The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 5(6), 335-346 (1995).
9. Desmeules J, Gascon MP, Dayer P et al.: Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol. 41, 23-26 (1991).
10. Gasche Y, Daali Y, Fathi M et al.: Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351(27), 2827-2831 (2004).
11. Koren G, Cairns J, Chitayat D et al.: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536), 704 (2006).
12. Madadi P, Ross CJ, Hayden MR et al.: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 85(1), 31-35(2009).
13. Chackalamannil S, Desai MC: Personalized medicine - a paradigm for a sustainable pharmaceutical industry? Curr. Opin. Drug Discov. Devel. 12, 443-445 (2009).
14. Thrall JH. Personalized medicine. Radiology 231, 613-616 (2004).
15. Atkinson AJ, Colburn WA, DeGruttola VG et al.: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Biomarkers Definitions Working Group. Clin. Pharmacol. Ther. 69, 89-95 (2001).
16. Clayton TA, Lindon JC, Cloarec O et al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006). ■■ Describes the potential of metabonomic profiling for understanding response to medications.
17. Mattes WB, Walker EG: Translational toxicology and the work of the predictive safety testing consortium Clin. Pharmacol. Ther. 85(3), 327-330 (2009).
18. Gieger C, Geistlinger L, Altmaier E et al.: Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 4(11), e1000282 (2008).
19. van der Greef J, Hankemeier T, McBurney RN: Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 7(7), 1087-1094 (2006).
20. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5, 835-843 (2004).
21. Hoskins JM, Goldberg RM, Qu P et al.: UGT1A1*28 genotype and irinotecaninduced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007).
22. Hudis C. A mechanism of action and use in clinical practice trastuzumab. N. Engl. J. Med. 357, 39-51 (2007).
23. Ross JS, Gray GS: Targeted therapy for cancer: the HER-2/neu and herceptin story. Clin. Leadersh. Manag. Rev. 17(6), 333-340 (2003).
24. Jimeno A, Messersmith WA, Hirsch FR et al.: KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J. 15(2), 110-113 (2009).
25. Lenz HJ, Chu E, Grothey A: KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. Clin. Adv. Hematol. Oncol. 6(12), 1-13 (2008).
26. Baynes RD, Gansert J: KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am. J. Ther. (2009) (Epub ahead of print).
27. Ley TJ, Mardis ER, Ding L et al.: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218), 66-72 (2008). ■■ Describes the whole-genome sequencing of a patient's acute myeloid leukemia genome. This represents a major advance in the development of personalized healthcare.
28. Williams IG: Enfuvirtide (Fuzeon): the first fusion inhibitor. Int. J. Clin. Pract. 57(10), 890-897 (2003).
29. Westby M, van der Ryst E: CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 16(6), 339-354 (2005).
30. Fätkenheuer G, Pozniak AL, Johnson MA et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11(11), 1170-1172 (2005).
31. Hunt JS, Romanelli F: Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 29(3), 295-304 (2009).
32. Nazari R, Joshi S: CCR5 as target for HIV-1 gene therapy. Curr. Gene Ther. 8(4), 264-272 (2008).
33. Low AJ, Swenson LC, Harrigan PR: HIV coreceptor phenotyping in the clinical setting. AIDS Rev. 10(3), 143-151 (2008).
34. Bruno Dubois, Howard H Feldman, Claudia Jacova et al.: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007). ■■ This position paper describes a proposal for the incorporation of revised criteria to update the diagnosis of Alzheimer's disease (AD) to include imaging and fluid biomarkers. The adoption of these criteria has the potential to identify patients much earlier in the disease progression.
35. McKhann G, Drachman D, Folstein M et al.: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7), 939-944 (1984).
36. Rowe CC, Ng S, Ackermann U et al.: Imaging b-amyloid burden in aging and dementia. Neurology 68(20), 1718-1725 (2007).
37. Klunk WE, Engler H, Nordberg A et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55(3), 306-319 (2004). ■■ First study that described the potential for the amyloid-imaging positron emission tomography tracer, termed Pittsburgh compound-B. This compound has provided valuable information on the progression of AD.
38. 42 could be used as predictive biomarkers of future dementia in cognitively normal individuals.
39. Hansson O, Zetterberg H, Buchhave P et al.: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5(3), 228-234 (2006). ■ Together with the Fagan et al. study, this was one of the first to provide longitudinal data on the potential for CSF fluid biomarkers to be useful in predicting the conversion from mild cognitive impairment to AD.
40. Ross CA, Margolis RL, Reading SA et al.: Neurobiology of schizophrenia. Neuron 52(1), 139-153 (2006).
41. Mattsson N, Zetterberg H, Hansson O et al.: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302(4), 385-393 (2009).
42. Petersen RC, Trojanowski JQ: Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. JAMA 302(4), 436-437 (2009).
43. Rosove MH, Grody WW: Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann. Intern. Med. 151(4), 270-273 (2009).
44. Hughes B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat. Rev. Drug Discov. 8(7), 523-524 (2009).
45. Personalized Medicine Coalition. www.personalizedmedicinecoalition.org
46. FDA Public Health Advisory. Use of codeine by some breastfeeding mothers may lead to life-threatening side effects in nursing babies. www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm054717.htm
47. Critical Path Institute. Predictive Safety Testing Consortium (PSTC). www.c-path.org/pstc.cfm
48. CAMPTOSAR Label FDA. www.accessdata.fda.gov/drugsatfda-docs/label/2002/ 20571s16lbl.pdf
49. Selzentry Label FDA. www.accessdata.fda.gov/drugsatfda-docs/label/2007/ 022128lbl.pdf
50. Biomarker validation From FDA Guidance for Industry: Pharmacogenomic data submissions, March 2005. www.fda.gov/cber/gdlns/pharmdtasub.pdf